Study examines safety and effectiveness of infliximab biosimilar in patients with inflammatory bowel disease

Biosimilars are biologic agents that highly similar to original biomedical medications (originators), but are much cheaper. A new study in Alimentary Pharmacology & Therapeutics found no differences in drug levels and disease activity between infliximab originator and an infliximab biosimilar in patients with inflammatory bowel disease, indicating that this biosimilar is indeed safe and effective.